Cargando…

Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization

AIM: To determine inter-reader agreement in categorization of imaging features using the Liver Imaging Reporting and Data System (LI-RADS) treatment response (LR-TR) algorithm in patients with hepatocellular carcinoma (HCC) treated with conventional transarterial chemoembolization (cTACE). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartnik, Krzysztof, Podgórska, Joanna, Rosiak, Grzegorz, Korzeniowski, Krzysztof, Rowiński, Olgierd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776670/
https://www.ncbi.nlm.nih.gov/pubmed/34581927
http://dx.doi.org/10.1007/s00261-021-03272-9
_version_ 1784636880824827904
author Bartnik, Krzysztof
Podgórska, Joanna
Rosiak, Grzegorz
Korzeniowski, Krzysztof
Rowiński, Olgierd
author_facet Bartnik, Krzysztof
Podgórska, Joanna
Rosiak, Grzegorz
Korzeniowski, Krzysztof
Rowiński, Olgierd
author_sort Bartnik, Krzysztof
collection PubMed
description AIM: To determine inter-reader agreement in categorization of imaging features using the Liver Imaging Reporting and Data System (LI-RADS) treatment response (LR-TR) algorithm in patients with hepatocellular carcinoma (HCC) treated with conventional transarterial chemoembolization (cTACE). METHODS: Two radiologists used the LR-TR algorithm to assess 112 computed tomography (CT) examinations of 102 patients treated with cTACE. The inter-observer agreement in categorization of LR-TR features was assessed using kappa (κ) statistics. RESULTS: There was substantial inter-observer agreement between the two reviewers using the LR-TR algorithm (κ = 0.70; 95% CI 0.58–0.81). The two reviewers categorized tumors as non-viable in 37 (33.0%) and 39 (34.8%) of 112 examinations, viable in 58 (51.8%) and 62 (55.4%) examinations, and equivocal in 18 (16.1%) and 11 (9.8%) examinations, respectively. There was almost perfect inter-observer agreement for the LR-TR non-viable category (κ = 0.80; 95% CI 0.68–0.92), substantial agreement for the viable category (κ = 0.78 95% CI 0.67–0.90), and fair agreement for the equivocal category (κ = 0.25; 95% CI 0.02–0.49). CONCLUSION: The LR-TR algorithm conveys high degrees of inter-observer agreement for the assessment of CT imaging features in the viable and non-viable categories. Further refinement of indeterminate features may be necessary to improve the correct categorization of equivocal lesions. GRAPHIC ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8776670
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-87766702022-02-02 Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization Bartnik, Krzysztof Podgórska, Joanna Rosiak, Grzegorz Korzeniowski, Krzysztof Rowiński, Olgierd Abdom Radiol (NY) Practice AIM: To determine inter-reader agreement in categorization of imaging features using the Liver Imaging Reporting and Data System (LI-RADS) treatment response (LR-TR) algorithm in patients with hepatocellular carcinoma (HCC) treated with conventional transarterial chemoembolization (cTACE). METHODS: Two radiologists used the LR-TR algorithm to assess 112 computed tomography (CT) examinations of 102 patients treated with cTACE. The inter-observer agreement in categorization of LR-TR features was assessed using kappa (κ) statistics. RESULTS: There was substantial inter-observer agreement between the two reviewers using the LR-TR algorithm (κ = 0.70; 95% CI 0.58–0.81). The two reviewers categorized tumors as non-viable in 37 (33.0%) and 39 (34.8%) of 112 examinations, viable in 58 (51.8%) and 62 (55.4%) examinations, and equivocal in 18 (16.1%) and 11 (9.8%) examinations, respectively. There was almost perfect inter-observer agreement for the LR-TR non-viable category (κ = 0.80; 95% CI 0.68–0.92), substantial agreement for the viable category (κ = 0.78 95% CI 0.67–0.90), and fair agreement for the equivocal category (κ = 0.25; 95% CI 0.02–0.49). CONCLUSION: The LR-TR algorithm conveys high degrees of inter-observer agreement for the assessment of CT imaging features in the viable and non-viable categories. Further refinement of indeterminate features may be necessary to improve the correct categorization of equivocal lesions. GRAPHIC ABSTRACT: [Image: see text] Springer US 2021-09-28 2022 /pmc/articles/PMC8776670/ /pubmed/34581927 http://dx.doi.org/10.1007/s00261-021-03272-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Practice
Bartnik, Krzysztof
Podgórska, Joanna
Rosiak, Grzegorz
Korzeniowski, Krzysztof
Rowiński, Olgierd
Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization
title Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization
title_full Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization
title_fullStr Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization
title_full_unstemmed Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization
title_short Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization
title_sort inter-observer agreement using the li-rads version 2018 ct treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization
topic Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776670/
https://www.ncbi.nlm.nih.gov/pubmed/34581927
http://dx.doi.org/10.1007/s00261-021-03272-9
work_keys_str_mv AT bartnikkrzysztof interobserveragreementusingtheliradsversion2018cttreatmentresponsealgorithminpatientswithhepatocellularcarcinomatreatedwithconventionaltransarterialchemoembolization
AT podgorskajoanna interobserveragreementusingtheliradsversion2018cttreatmentresponsealgorithminpatientswithhepatocellularcarcinomatreatedwithconventionaltransarterialchemoembolization
AT rosiakgrzegorz interobserveragreementusingtheliradsversion2018cttreatmentresponsealgorithminpatientswithhepatocellularcarcinomatreatedwithconventionaltransarterialchemoembolization
AT korzeniowskikrzysztof interobserveragreementusingtheliradsversion2018cttreatmentresponsealgorithminpatientswithhepatocellularcarcinomatreatedwithconventionaltransarterialchemoembolization
AT rowinskiolgierd interobserveragreementusingtheliradsversion2018cttreatmentresponsealgorithminpatientswithhepatocellularcarcinomatreatedwithconventionaltransarterialchemoembolization